PHAXIAM Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de PHAXIAM Therapeutics es Thibaut Fayet , nombrado en Jun 2023, tiene una permanencia de 1.25 años. compensación anual total es €391.73K, compuesta por 34.5% salario y 65.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.055% de las acciones de la empresa, por valor de €9.23K. La antigüedad media del equipo directivo y de la junta directiva es de 1.5 años y 11.3 años, respectivamente.

Información clave

Thibaut Fayet

Chief Executive Officer (CEO)

€391.7k

Compensación total

Porcentaje del salario del CEO	34.5%
Permanencia del CEO	1.3yrs
Participación del CEO	0.05%
Permanencia media de la dirección	1.5yrs
Promedio de permanencia en la Junta Directiva	11.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Thibaut Fayet en comparación con los beneficios de PHAXIAM Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	€392k	€135k	-€23m

Compensación vs. Mercado: La compensación total ($USD432.80K) de Thibaut está en línea con el promedio de empresas de tamaño similar en el mercado UK ($USD354.57K).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Thibaut con los resultados de la empresa.

CEO

Thibaut Fayet (56 yo)

1.3yrs

Permanencia

€391,725

Compensación

Mr. Thibaut du Fayet serves as Chief Executive Officer at PHAXIAM Therapeutics S.A. since June 23, 2023. He served as Chief Operating Officer and served as Member of the Executive Board at Pherecydes Pharm...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Thibaut Fayet	Chief Executive Officer	1.3yrs	€391.73k	0.055% € 9.2k
Eric Soyer	Deputy CEO	9yrs	€481.41k	0.0063% € 1.1k
Jérôme Bailly	Deputy CEO	4.7yrs	€262.41k	0.0038% € 637.9
Cindy Fevre	Chief Scientific Officer	1.7yrs	sin datos	sin datos
Naomi Eichenbaum	Director Investor Relations	no data	sin datos	sin datos
Anne-Cécile Fumey	Vice President of Human Resources	8.6yrs	sin datos	0.00086% € 144.4
Karine Charton	Chief Business Officer	1.3yrs	sin datos	0.00040% € 67.1
Pascal Birman	Chief Medical Officer	1.3yrs	sin datos	sin datos
Frederique Vieville	Chief Regulatory Officer	1.3yrs	sin datos	sin datos
Philip Lorenzi	Consultant & Member of Scientific Board	no data	sin datos	sin datos
Eric Raymond	Consultant & Member of Scientific Board	no data	sin datos	sin datos
Bridget Bax	Consultant & Member of Scientific Board	no data	sin datos	sin datos

1.5yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de PHXMP no se considera experimentado ( 1.5 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Philip Lorenzi	Consultant & Member of Scientific Board	14.7yrs	sin datos	sin datos
Eric Raymond	Consultant & Member of Scientific Board	14.9yrs	sin datos	sin datos
Bridget Bax	Consultant & Member of Scientific Board	12.7yrs	sin datos	sin datos
Arthur Frankel	Consultant & Member of Scientific Board	12.7yrs	sin datos	sin datos
Kurt Gunter	Consultant & Member of Scientific Board	12.7yrs	sin datos	sin datos
Philippe Archinard	Independent Director	11.3yrs	€68.00k	0.010% € 1.7k
Gil Beyen	Vice Chairman	11.3yrs	€1.00m	0.0049% € 814.2
Hilde Windels	Independent Director	10yrs	€56.75k	0.000010% € 1.7
Didier Hoch	Chairman of the Board	1.3yrs	€153.18k	sin datos
Leila Nicolas	Representative Director	1.3yrs	€26.25k	sin datos
Robert Sebbag	Independent Director	1.3yrs	€21.75k	sin datos
Valerie Faillat	Independent Director	less than a year	sin datos	sin datos

11.3yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de PHXMP son experimentados ( 11.3 años antigüedad media).

PHAXIAM Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

Recent updates

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in U.S

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

Insufficient new directors

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

Insufficient new directors

No longer forecast to breakeven

No longer forecast to breakeven

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

No longer forecast to breakeven

No longer forecast to breakeven

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2023

Revenue misses expectations

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad